$13.210
-1.737 (-13.15%)收盘时
SLS 盈利能力与利润率
Evaluating the bottom line, Sellas Life Sciences Group Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -39.63%, provide a clear picture of how effectively SLS converts its operational activities into shareholder value.
SLS 同业对比
In the context of the broader market, SLS competes directly with industry leaders such as ATAI and VRDN. With a market capitalization of $2.67B, it holds a significant position in the sector. When comparing efficiency, SLS's gross margin of N/A stands against ATAI's 100.00% and VRDN's 100.00%. Such benchmarking helps identify whether Sellas Life Sciences Group Inc is trading at a premium or discount relative to its financial performance.
Sellas Life Sciences Group Inc 财务表现
The company has shown a remarkable year-over-year change of +621.86%, indicating strong growth in stock performance, despite ongoing net losses.
Financials
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。